Monday, August 2, 1993
Cash not forcing Oclassen IPO
With break-even cash flow from product sales and a full pipeline of later-stage
products in the clinic, Oclassen Pharmaceuticals Inc. has seemed especially fitted to the
increasingly rigorous demands of the Street.
But its proposed IPO of 3 million shares at $17 to $19 per share, which was registered
in January, has languished in the stale offerings market and the company now must consider
whatever effects may result